Clinical Trials on Psoriasis in Norway

Total 92 results

Diakonhjemmet Hospital
The Dam Foundation; The Norwegian Rheumatism Association; Norwegian Health Association

Completed

Improved Cardiovascular Health for Patients With Inflammatory Joint Diseases (ExeHeart)

Rheumatoid Arthritis | Psoriatic Arthritis | Spondyloarthritis

Norway
Diakonhjemmet Hospital
Aarhus University Hospital; University Hospital, Umeå

Recruiting

The Effect of Brief Versus Individually Tailored Dietary Advice on Change in Lipids, Blood Pressure, and Diet in Patients With Inflammatory Joint Disease

Rheumatoid Arthritis | Psoriatic Arthritis | Spondyloarthritis

Norway
Norwegian University of Science and Technology

Terminated

Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

Plaque Psoriasis

Norway
Helse Forde

Recruiting

Accelerometry in Follow up of Arthritis - a Pilot Study (WIAp)

Arthritis, Rheumatoid | Psoriatic Arthritis | Spondyloarthritis

Norway
Norwegian University of Science and Technology
Helse Møre og Romsdal HF

Completed

Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis

Arthritis, Psoriatic | Spondylarthropathies | Spondylarthritis | Spondylitis, Ankylosing | Sacroiliitis

Norway
Diakonhjemmet Hospital

Recruiting

Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis (NOR-SPRINT)

Psoriatic Arthritis

Norway
Arctic Nutrition AS
University of Bergen; Haukeland University Hospital

Completed

Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis

Psoriasis Vulgaris

Norway
Revmatismesykehuset AS
Abbott

Completed

Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment (PSARA)

Rheumatoid Arthritis | Endothelial Dysfunction | Psoriatic Arthritis | Ankylosing Spondylitis | Inflammatory Disease Activity

Norway
Oslo University Hospital
University of Oslo

Unknown

Psoriasis and Climate Therapy- Effect of Motivational Follow- up Calls on Clinical and Health Economic Parameters

Psoriasis

Norway
Diakonhjemmet Hospital
University Hospital, Akershus

Active, not recruiting

Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication (Nor-vaC)

Rheumatoid Arthritis | Crohn Disease | Ulcerative Colitis | Autoimmune Hepatitis | Psoriatic Arthritis | Liver Transplant; Complications | Spondyloarthritis

Norway
Oslo University Hospital

Unknown

Psoriasis and the Risk of Cardiovascular Disease. A Prospective Study

Cardiovascular Disease | Psoriasis

Norway
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

Psoriasis | Arthritis, Psoriatic

Finland, Denmark, Norway, Sweden
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis

Psoriasis of Scalp

Canada, Denmark, France, Norway, Portugal, Spain, Sweden, United Kingdom
University Hospital of North Norway
University of Tromso; Cornell University; The Royal Norwegian Ministry of Health

Completed

The Effect of Vitamin D Supplementation on Psoriasis Severity

Psoriasis | Vitamin D Deficiency

Norway
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis (EQUATOR)

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Bristol-Myers Squibb

Terminated

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Psoriatic Arthritis

Argentina, France, Italy, United States, Canada, Belgium, Netherlands, Australia, Germany, South Africa, Spain, Norway
Galapagos NV

Terminated

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Diakonhjemmet Hospital
South-Eastern Norway Regional Health Authority

Completed

The NOR-SWITCH Study (NOR-SWITCH)

Rheumatoid Arthritis | Crohn's Disease | Ulcerative Colitis | Psoriatic Arthritis | Spondyloarthritis | Psoriasis Chronic

Norway
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Centocor, Inc.

Completed

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Canada, Switzerland, Finland, Denmark
Eli Lilly and Company

Completed

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3)

Psoriatic Arthritis

Spain, Bulgaria, Czechia, Estonia, Mexico, Poland, Ukraine, United States, South Africa, Russian Federation, Slovakia, United Kingdom
Dong-A ST Co., Ltd.
Meiji Seika Pharma Co., Ltd.

Completed

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis (Opportuniti)

Moderate to Severe Chronic Plaque Psoriasis

United States
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Australia, Czechia, Hungary, Serbia, Slovakia, Estonia, Spain, Russian Federation, Lithuania, Bulgaria
Diakonhjemmet Hospital
Oslo University Hospital; University Hospital, Akershus

Completed

The Norwegian Drug Monitoring Study (NOR-DRUM)

Rheumatoid Arthritis | Psoriasis | Crohn Disease | Ulcerative Colitis | Psoriatic Arthritis | Ankylosing Spondylitis | Spondyloarthritis

Norway
Takeda
Nimbus Lakshmi, Inc.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Czechia, Germany, Poland
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE COMPLETE)

Psoriatic Arthritis

United States, Australia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Sun Pharmaceutical Industries Limited

Completed

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Psoriatic Arthritis

United States, Argentina, Hungary, Mexico, Poland, Russian Federation, Spain, Ukraine
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
UCB Biopharma SRL

Active, not recruiting

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE VITAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H)

Psoriatic Arthritis

Belgium, Hungary, Canada, India, Israel, Italy, Australia, Netherlands, United Kingdom, Mexico, Switzerland, South Africa, Poland, Finland, Argentina, France, Germany, Ukraine, Spain, Austria, Denmark, Sweden
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Bristol-Myers Squibb

Recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Italy, United States, Australia, Argentina, Brazil, Czechia, France, Hungary, Mexico, Russian Federation, China, Poland, Finland, Colombia, United Kingdom, Bulgaria, Taiwan, Chile, Romania, Spain, Ireland
MoonLake Immunotherapeutics AG

Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Spain, Bulgaria, Poland, Czechia, Estonia, Germany, Hungary
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Akros Pharma Inc.

Completed

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)

Skin Diseases | Psoriasis | Plaque Psoriasis

United States, Canada, Poland
Novartis Pharmaceuticals

Completed

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Chronic Plaque-type Psoriasis

United States
Janssen Research & Development, LLC

Completed

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Arthritis, Psoriatic

United States, Australia, Poland, United Kingdom, Germany, Spain, Canada, Finland, New Zealand, Russian Federation, Austria, Hungary, Lithuania, Latvia
Janssen Research & Development, LLC

Completed

A Study of Golimumab in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

Poland, Ukraine, United States, Germany, Belarus, Spain, Romania, Russian Federation, Hungary, Lithuania, Australia, Canada
Janssen Research & Development, LLC

Active, not recruiting

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (VISIBLE)

Plaque Psoriasis | Scalp Psoriasis

United States, Canada
Samsung Bioepis Co., Ltd.
Organon and Co

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Czechia, Lithuania, Poland, Bulgaria
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

Arthritis, Psoriatic

Italy, Germany, Taiwan, United States, Malaysia, Turkey, Georgia, Canada, Hong Kong, Portugal, Denmark, Israel, Philippines, Thailand, Bulgaria, Australia, Czechia, Hungary, Poland, Russian Federation, Ukraine, Spain, Argentina, United... and more
Novartis Pharmaceuticals

Completed

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

Plaque-type Psoriasis

Germany, United States, Japan, France, Norway, Israel, Iceland
Alumis Inc

Active, not recruiting

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Plaque Psoriasis

United States, Canada
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE)

Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
Dermavant Sciences GmbH
IQVIA Biotech

Completed

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

Plaque Psoriasis

United States, Canada
Polichem S.A.
Almirall, S.A.

Withdrawn

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s

Nail Psoriasis

United States
Novartis Pharmaceuticals

Completed

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Chronic Plaque-type Psoriasis

Germany, United States, Japan, France, Israel, Norway, Iceland
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland

Clinical Trials on Psoriasis in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations